Purple Biotech (PPBT)
NASDAQ:PPBT
Total Valuation
Purple Biotech has a market cap or net worth of $5.93M. The enterprise value is -$6.76M.
Market Cap$5.93M
Enterprise Value-$6.76M
Share Statistics
Purple Biotech has 929,240 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding929,240
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Purple Biotech’s return on equity (ROE) is -2.76 and return on invested capital (ROIC) is -69.87%.
Return on Equity (ROE)-2.76
Return on Assets (ROA)-1.53
Return on Invested Capital (ROIC)-69.87%
Return on Capital Employed (ROCE)-0.72
Revenue Per Employee0.00
Profits Per Employee-2.98M
Employee Count9
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Purple Biotech is ―. Purple Biotech’s PEG ratio is >-0.00001.
PE Ratio―
PS Ratio0.00
PB Ratio<0.01
Price to Fair Value<0.01
Price to FCF>-0.01
Price to Operating Cash Flow-0.55
PEG Ratio>-0.00001
Income Statement
In the last 12 months, Purple Biotech had revenue of 0.00 and earned -26.81M in profits. Earnings per share was -11.08K.
Revenue0.00
Gross Profit-204.61K
Operating Income-7.03M
Pretax Income-26.70M
Net Income-26.81M
EBITDA-6.83M
Earnings Per Share (EPS)-11.08K
Cash Flow
In the last 12 months, operating cash flow was -5.57M and capital expenditures 2.05M, giving a free cash flow of -3.52M billion.
Operating Cash Flow-5.57M
Free Cash Flow-3.52M
Free Cash Flow per Share-3.79
Dividends & Yields
Purple Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.68
52-Week Price Change-84.02%
50-Day Moving Average5.06
200-Day Moving Average10.91
Relative Strength Index (RSI)47.97
Average Volume (3m)415.61K
Important Dates
Purple Biotech upcoming earnings date is May 27, 2026, TBA (Confirmed).
Last Earnings DateFeb 11, 2026
Next Earnings DateMay 27, 2026
Ex-Dividend Date―
Financial Position
Purple Biotech as a current ratio of 1.27, with Debt / Equity ratio of 2.51%
Current Ratio1.27
Quick Ratio1.27
Debt to Market Cap15.47
Net Debt to EBITDA1.24
Interest Coverage Ratio-7.10
Taxes
In the past 12 months, Purple Biotech has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Purple Biotech EV to EBITDA ratio is 1.24, with an EV/FCF ratio of 1.53.
EV to Sales0.00
EV to EBITDA1.24
EV to Free Cash Flow1.53
EV to Operating Cash Flow1.53
Balance Sheet
Purple Biotech has $9.57M in cash and marketable securities with $244.00K in debt, giving a net cash position of $9.33M billion.
Cash & Marketable Securities$9.57M
Total Debt$244.00K
Net Cash$9.33M
Net Cash Per Share$10.04
Tangible Book Value Per Share$957.80
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Purple Biotech is $30.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$30.00
Price Target Upside599.30% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast88.64%